2024
Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries
Prunas O, Shioda K, Toscano C, Bastias M, Valenzuela-Bravo M, Tito J, Warren J, Weinberger D, de Oliveira L. Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries. The Journal Of Infectious Diseases 2024, jiae144. PMID: 38502711, DOI: 10.1093/infdis/jiae144.Peer-Reviewed Original ResearchAll-cause pneumoniaPneumonia deathsPneumonia mortalityAge groupsPneumococcal conjugate vaccineProportion of IPD casesInvasive pneumococcal diseaseMulti-country studyIPD casesOlder age groupsPopulation-level impactMortality dataYears of ageInvasive pneumococcal disease casesConjugate vaccinePneumococcal conjugate vaccine introductionEffect of pneumococcal conjugate vaccinesTemporal trendsImpact of pneumococcal conjugate vaccinesUnvaccinated age groupsMortalityEvaluate changesPost-vaccination periodVaccine serotypesNo significant changes
2011
Serotype replacement in disease after pneumococcal vaccination
Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. The Lancet 2011, 378: 1962-1973. PMID: 21492929, PMCID: PMC3256741, DOI: 10.1016/s0140-6736(10)62225-8.Peer-Reviewed Original ResearchConceptsNon-vaccine serotypesSerotype replacementPneumococcal diseaseHeptavalent pneumococcal conjugate vaccinePneumococcal conjugate vaccineImportant public health benefitsBenefits of vaccinationPublic health benefitsDisease surveillance systemsNVT carriagePneumococcal vaccinationSurveillance biasesConjugate vaccineVaccine serotypesCarriage prevalencePneumococcal serotypesAsymptomatic carriersCarriage dataDiseaseVaccinationHealth benefitsLow invasivenessPrevalenceSerotypesCarriage